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The Von Hippel-Lindau (VHL) syndrome has been rarely associated with renal oncocytomas, and tumors usually show
HIF1α chronic stabilization. By contrast, oncocytomas mainly associated with respiratory chain (RC) defects due to severe
mitochondrial DNA (mtDNA) mutations are incapable of stabilizing HIF1α, since oxygen consumption by the RC is
dramatically diminished and prolylhydroxylase activity is increased by α-ketoglutarate accumulation following Krebs cycle
slowdown. Here, we investigate the cooccurrence of a pseudohypoxic condition with oncocytic transformation in a case of
VHL-associated renal oncocytoma. While HIF1α was abundant in nuclei concordantly with defects in VHL, negative
staining of its targets carbonic anhydrase IX (CAIX) and glucose transporter GLUT1, usually overexpressed in
VHL-associated neoplasms, suggested HIF1α to be present in its inactive (hydroxylated) form. MtDNA sequencing and
immunohistochemistry analyses revealed a MT-CO1 stop-gain mutation and cytochrome c oxidase loss. We suggest that a
mitochondrial respiration impairment may lead to hyperhydroxylation of the transcription factor, which we confirmed by
specific staining of hydroxylated HIF1α. Such inactive form hence accumulated in the VHL-deficient tumor, where it may
contribute to the benign nature of the neoplasm. We propose that the protumorigenic role of HIF1α in VHL cancers may
be blunted through drugs inhibiting mitochondrial respiratory complexes, such as metformin.
1. Introduction
Von Hippel-Lindau (VHL) disease is a genetic condition
characterized by the predisposition to develop tumors of
the central nervous system, such as hemangioblastoma of
the cerebellum, in addition to clear cell Renal Cell Cancer
(ccRCC). Pheochromocytoma and pancreatic cancer have also
been reported in patients harboring germ line VHLmutations
[1]. A commonmolecular feature shared by such neoplasms is
the chronic stabilization of the Hypoxia-Inducible Factor 1α
(HIF1α) even in normoxia (pseudohypoxia). The tumor sup-
pressor VHL encodes a ubiquitin ligase enzyme that presides
to constant HIF1α degradation in the presence of molecular
oxygen, when the transcription factor is hydroxylated by pro-
lylhydroxylase domain-containing (PHD) enzymes for VHL
recognition and proteasome degradation [2]. A lack of VHL
leads to HIF1α activation sustaining a protumorigenic meta-
bolic reprogramming towards Warburg’s glycolytic shift, as
well as a promotion of neoangiogenesis, since HIF1α positively
regulates both glycolytic enzymes and the vascular endothelial
growth factor (VEGF). Such protumorigenic changes, on the
contrary, do not occur in benign sporadic kidney oncocyto-
mas, i.e., renal tumors characterized by cells with a marked
mitochondrial hyperplasia and a scarce vascularization. This
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is due to the inability of the tumor to stabilize HIF1α follow-
ing the occurrence of pathogenic mitochondrial DNA
(mtDNA) mutations [3], a distinctive hallmark of renal
oncocytoma [4]. Here, we report for the first time a case of
VHL-associated renal oncocytoma whose mtDNA genetic
hallmark, a highly pathogenic mutation in respiratory Com-
plex IV (CIV), was associated with the unique phenotype of
undegraded, hyperhydroxylated, and dysfunctional HIF1α,
suggesting that mtDNA mutations are potent modifiers
in cancer.
2. Materials and Methods
2.1. Mitochondrial DNA Sequencing, Haematoxylin-Eosin
Staining, and Immunohistochemical Analysis. Analyses were
performed on FFPE sections of the proband’s renal oncocy-
toma. 10μm-thick slides were obtained for total DNA
extraction with a commercial kit (Promega), and whole
mtDNA sequencing and analysis were performed as previ-
ously described [5]. 4μm-thick FFPE serial sections were
used for haematoxylin-eosin staining (H&E) and immuno-
histochemical (IHC) analysis. The following primary anti-
bodies were applied: mouse monoclonal anti-mitochondrial
COXI (clone 1D6E1A8, Abcam Ltd., UK) diluted 1 : 800;
mouse monoclonal anti-HIF1α (clone H1alpha67, Thermo
Fisher Scientific, USA) diluted 1 : 600; rabbit monoclonal
anti-hydroxy-HIF-1α (clone D43B5, Cell Signaling Tech-
nology, USA) diluted 1 : 400; and mouse monoclonal anti-
OxPhos Complex V, subunit D (clone 7F9, Invitrogen Co.,
CA, USA) diluted 1 : 1000. Sections were dewaxed, rehy-
drated, and subjected to antigen retrieval treatment in a water
bath at 98.5°C using citrate buffer pH6.0 (40min) for anti--
HIF1α or Tris-EDTA buffer pH9.0 (20min) for anti-COXI
and anti-Complex V, subunit D. Endogenous peroxidase
activity was inhibited using a 0.5% H2O2 solution in metha-
nol for 20min at room temperature. Sections were incubated
overnight at 4°C and then processed using a nonbiotin-
amplified method (Novolink, Novocastra) according to the
manufacturer’s protocols. The immunologic reaction was
developed using a 3,3′-diaminobenzidine (DAB)/H2O2 PBS
pH7.2-7.4 solution for 10min. Sections were then washed
in distilled water, counterstained in Harris haematoxylin,
dehydrated, and mounted with Bio Mount HM (Bio Optica,
Milan Italy). The immunological reaction for anti-CAIX
(clone TH-22, Novocastra, UK) diluted 1 : 100 and rabbit
polyclonal anti-GLUT1 (Cell Marque, USA) RTU was con-
ducted in a BenchMark ULTRA autostainer (Ventana Medi-
cal Systems, USA). Sections were retrieved with Ultra CC1 at
95°C (CAIX—32min, GLUT1—24min) and incubated at
36°C for 28min with the proper antibody. The immunologic
reaction was visualized using an OptiView DAB detection kit
following the manual instructions.
2.2. Immunohistochemical Quantification. The quantitative
score (QS) for each protein in control and tumor tissue was
evaluated at a magnification of 200x as previously reported
[6]. The QS is then expressed as the product of the percentage
of positive cells (P) and the staining intensity (I). The final QS
is a value within the range of 0 (negative staining) and 12
(strong positive staining).
2.3. Ethics Approval and Consent to Participate. The patient
was enrolled in the TRANSMIT study (protocol number
26/2009/U/Tess 03/03/2009) approved by the local ethical
committee at S. Orsola Hospital, Bologna.
3. Results
3.1. Case Histology Reveals a Typical Renal Oncocytoma. The
case was retrieved from a previous study in which a
40-year-old male had been diagnosed with hemangioblas-
toma of the cerebellum and renal oncocytoma with a germ-
line VHL mutation [7]. The patient’s renal tumor was in
fact revealed to be a typical oncocytoma located in the lower
pole of the right kidney visualized with echography as a
well-circumscribed nodule. Macroscopically, the neoplasm
measured 3.5 cm across, displayed neat borders, and had a
brownish color in the cut surface. The case was brought to
our attention with the aim to understand how a pseudohy-
poxic condition may coexist with the oncocytic phenotype,
whose molecular signature is the occurrence of mtDNA
mutations leading to HIF1α chronic destabilization [3].
Genetic analyses had previously revealed that the patient har-
bored an 11 bp duplication in the promoter region of VHL,
whose functional investigation showed an impaired gene
expression of the mutated allele, hence explaining the VHL
syndromic phenotype of the subject [7]. Histologically, the
tumor was constituted by cells of similar size arranged along
regular trabeculae. Cells showed round and regular nuclei.
Mitoses were rare. No necrotic areas were seen. Almost all
tumor cells displayed intense and diffuse eosinophilic cyto-
plasmic granularity (Figure 1(a)) consequent to mitochon-
drial overload as observed with the positive anti-OxPhos
antibody (Figures 1(b)-1(c)).
3.2. A Peculiar HIF1α Dysfunction Occurs within the Renal
Oncocytoma. Since VHL-associated tumors usually show a
functional HIF1 even in normoxia, we proceeded to perform
IHC for the HIF1α subunit, which we expected to be positive,
as the effect of VHL loss of function mutations is HIF1α
chronic stabilization due to lack of proteasomal degradation.
Indeed, HIF1α was abundant in nearly all oncocytic cells
within the tumor mass compared to the normal tissue
(Figure 2(a)-2(b)), confirming this to be a neoplasm with
defective VHL. Nonetheless, HIF1α stabilization is usually
not a feature of benign oncocytomas, which prompted us to
investigate further how such a marker of malignancy may
have occurred in this case. Staining for HIF1α target car-
bonic anhydrase IX (CAIX), used as an endogenous marker
for tumor hypoxia in VHL-deficient renal cell carcinomas
[8], surprisingly revealed negative cells throughout the mass
(Figure 2(c)-2(d)). This result was also corroborated by the
negative staining for GLUT1 in the renal oncocytoma
(Figure 2(e)-2(f)), another well-known HIF1 target usually
found to be positive in cancer hypoxic regions. The negative
staining of both CAIX and GLUT1 was in apparent disagree-
ment with the positive HIF1α staining, and it suggested that
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HIF1α was retained in its hydroxylated status and therefore
lacking transcriptional activity.
3.3. Damage to the Mitochondrial Respiratory Chain May
Underlie the Oncocytic Phenotype. Regardless of its abun-
dance in the VHL tumor, a dysfunctional HIF1α was consis-
tent with the oncocytic phenotype and its benign nature. In
order to understand the cause for such lack of transcriptional
activity despite its nuclear accumulation, we performed
whole mitochondrial DNA sequencing with the aim to reveal
pathogenic mutations that may impede a proper HIF1α func-
tioning. The rationale for this approach was that mtDNA
mutations hampering the activity of the respiratory chain
trigger an imbalance of the NAD+/NADH ratio with con-
sequent slowdown of the Krebs cycle rate. The latter may
contribute to the accumulation of α-ketoglutarate, foster-
ing the activity of PHDs [9]. In VHL-competent cells,
PHDs would contribute to destabilize HIF1α, whereas in
our VHL-deficient case we hypothesized that HIF1α should
be still hyperhydroxylated, but not directed to the protea-
some for degradation.
The screening of the tumor for mtDNA genetic lesions
indeed revealed a stop-gain mutation in the MT-CO1 gene
(m.6129G>A) (Figure 3(a)-3(b)), encoding COXI, one
of the three mtDNA subunits for respiratory CIV. The
mutation was novel as it was not reported in the reference
human mtDNA database HmtDB, http://www.hmtdb.
uniba.it/hmdb/ [10], and it was strikingly homoplasmic.
IHC staining for COXI was indeed negative in cancer cells
(Figure 3(c)-3(d)), suggesting that CIV was not properly
assembled.
Hence, we stained the renal oncocytoma for the
hydroxylated form of HIF1α with the aim to understand
whether the HIF1α positivity we observed (Figure 2(a))
was indeed due to the inactive form of the transcription
factor, unable to be degraded in a VHL-deficient context.
Indeed, a marked positive staining compared to control
(Figure 3(e)-3(f)) indicated the accumulation of transcrip-
tionally inactive hydroxylated HIF1α.
4. Discussion
Very few cases of renal oncocytoma occurring in the con-
text of a VHL syndrome have been described [11, 12],
underlining the extremely low prevalence of this type of
benign neoplasm when VHL is mutated. This is likely
due to the fact that the functional trigger for tumorigen-
esis in the presence of VHL mutations is HIF1α chronic
stabilization, as loss of function mutations of the tumor
suppressor lead to a lack of HIF1α ubiquitination and
subsequent proteasome-mediated degradation. The latter,
nonetheless, depends on a functional mitochondrial respira-
tory chain, since a block of activity allows both intracellular
oxygen and NADH to accumulate, leading in turn to
increased levels of α-ketoglutarate, feeding the PHD reaction
[13]. In this clinical case, we detected a mtDNA mutation in
CIV, which may have well triggered oncocytic transforma-
tion through, possibly, a compensatory effect to overcome
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Figure 2: IHC analysis of HIF1α and its targets. (a, b) IHC for
HIF1α in the renal oncocytoma (a) with a QS of 12 (P = 4, I = 3)
and in a normal kidney used as control (b) with a QS of 1 (P = 1,
I = 1). (c, d) IHC for CAIX in the renal oncocytoma (c) with a QS
of 0 (P = 0, I = 0) and in a clear cell renal cell carcinoma used as
positive control (d) with a QS of 10 (P = 4, I = 2 5). (e, f) IHC of
GLUT1 in the renal oncocytoma (e) with a QS of 0 (P = 0, I = 1)
and in a hypoxic area of a neuroendocrine carcinoma of the ovary
used as positive control (f) with a QS of 12 (P = 4, I = 3).
Magnification for all IHC images: 200x.
(a) (b) (c)
H&E Complex V
Figure 1: H&E staining and IHC characterization of the renal oncocytoma from the patient carrying the germline VHL deletion. (a) H&E
staining of tumor tissue. (b, c) IHC for Complex V, subunit D in the renal oncocytoma (b) and in a normal kidney used as control (c),
both with a QS of 8 (P = 4, I = 2). Magnification for all IHC images: 200x.
3Oxidative Medicine and Cellular Longevity
the bioenergetic deficit. Such a severe homoplasmic mutation
occurred in a bottleneck complex of the respiratory chain,
whose negative staining strongly suggests that a severe ener-
getic impairment may occur in these cells, hence explaining
the indolent nature of the oncocytic neoplasm.
Therefore, on one hand the derangement of the respira-
tory chain would promote HIF1α hydroxylation and, on
the other, the absence of VHL-mediated degradation would
allow accumulation of inactive HIF1α. Hydroxylation on
the HIF1α C-terminal activator domain impairs the interac-
tion between HIF1α and the CBP/p300 coactivators, abolish-
ing HIF1α transactivation activity [14]. Therefore, a severe
dysfunction of the respiratory chain here may have
favored the accumulation of high levels of hydroxylated
HIF1α as shown by IHC. The low-functional HIF1α would
not help to drive hypoxia response and to trigger the protu-
morigenic Warburg effect, as suggested by the negative CAIX
and GLUT1 staining, a mechanism previously reported also
as a result of respiratory Complex I disassembly and a dys-
functional cytochrome c [3, 15]. Along with a hampered
respiratory chain, this would further contribute to maintain-
ing the tumor in a low-proliferative and low-aggressive state
by slowing down HIF1-dependent glycolysis; it is plausible to
envision that this tumor may switch to the reductive carbox-
ylation of glutamine to thrive, a metabolic route activated in
the presence of severe mtDNA mutations [16]. Altogether,
our data point to mtDNA mutations as potent modifiers
of a cancer phenotype and fate. Further investigation of such
mechanisms is warranted as targeted pharmacological
derangement of the respiratory chain, i.e., through metfor-
min [17, 18], may be useful as an adjuvant treatment for
VHL tumors to dampen the effects of HIF1α chronic stabili-
zation and hence tumorigenic potential.
Data Availability
The mtDNA sequence of the oncocytic tumor described in
this paper has been deposited in the Human Mitochondrial
DataBase HmtDB [10] and may be retrieved with the follow-
ing identifier: PA_EU_IT_0276.
Conflicts of Interest
The authors declare that there is no conflict of interest
regarding the publication of this paper.
Acknowledgments
We are grateful to Professor V. Eusebi for critically reading
and revising the manuscript. This work was supported by
the Italian Ministry of Health project DISCO TRIP (grant
number GR-2013-02356666), by the Italian Association for
Cancer Research (AIRC) grant JANEUTICS (grant number
IG14242), and by the Worldwide Cancer Research grant
DHOMOS to GG (grant number 15-1144). MDL is sup-
ported by a triennial AIRC fellowship “Bruna Martelli.”
(a) (b)
(c) (d)
(e) (f)
MT-CO1
COXI
OH-HIF1훼
A A T C G G A G G A A T C A G A G G
Figure 3: Genetic and IHC characterization of the renal oncocytoma from the patient carrying the germline VHL deletion. (a, b)
Chromatograms showing a reference (a) and the tumor sequence with the somatic homoplasmic m.6129G>A stop-gain mutation found in
MT-CO1 (b). (c, d) IHC for COXI in the renal oncocytoma (c) with a QS of 0 (P = 0, I = 1) and in a normal kidney used as control (d)
with a QS of 12 (P = 4, I = 3). (e, f) IHC for hydroxylated HIF1α (OH-HIF1α) in the renal oncocytoma (e) with a QS of 8 (P = 4, I = 2)
and in the same hypoxic neuroendocrine carcinoma of the ovary stained for GLUT1 in Figure 2 used as control (f) with a QS of 0 (P = 0,
I = 1). Magnification for all IHC images: 200x.
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